Edison IA
Edison IA helps small and mid-sized businesses put AI to work through executive training, process diagnosis and deployed business agents.
€1MSeed
ParticipantB
Bpifrance
Activity from announced rounds
Activity in this selectionSep 30, 2026 · Sep 1, 2026
Bpifrance is France’s public investment bank, financing businesses through equity, loans and guarantees and supporting innovation and international expansion.
Its equity activity includes venture capital, growth investment and investments in other funds. Innovation financing can also support research, development and bringing a product to market, so founders may have financing options beyond a conventional equity round.
The appropriate route depends on the project and stage: research funding, a guarantee for borrowing, direct investment and export support serve different needs. Its bank-for-entrepreneurs model connects those instruments with programmes for developing a French business.
Sources
- Rounds participated in
- 6
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $98.3M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
1 more
Fintech1
By country
Rounds
6 in this selectionHackuity
Hackuity consolidates vulnerability findings from security tools and helps organisations prioritise remediation against their actual exposure.
$19MSeries B
ParticipantDelos
Delos sells autonomous AI workers that take on defined business tasks through a company’s messaging and software tools.
€10MSeries A
ParticipantKaiko
Market data, analytics and infrastructure that help financial institutions price, trade and manage risk in digital assets.
$57MSeries B-2 extension
ParticipantEd.ai
AI assessment software that helps teachers turn exam papers into editable grading rubrics, review assisted marking and target students’ learning gaps.
€5MSeed
ParticipantOne Biosciences
Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development.
€3.3Mi-Démo 5 grant (France 2030)
Participant